{"id":15903,"date":"2022-11-03T13:40:39","date_gmt":"2022-11-03T08:10:39","guid":{"rendered":"http:\/\/finservwealth.com\/alembic-gets-usfda-nod-for-generic-pain-relief-medication\/"},"modified":"2022-11-03T13:40:39","modified_gmt":"2022-11-03T08:10:39","slug":"alembic-gets-usfda-nod-for-generic-pain-relief-medication","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/alembic-gets-usfda-nod-for-generic-pain-relief-medication\/","title":{"rendered":"Alembic gets USFDA nod for generic pain-relief medication"},"content":{"rendered":"<p> The company has received final approval from the US Food  Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Ketorolac Tromethamine Injection In multiple strengths, the drug maker said in a statement.<\/p><div id=\"finse-4238110405\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/business\/alembic-gets-usfda-nod-for-generic-pain-relief-medication_16686861.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>The company has received final approval from the US Food Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Ketorolac Tromethamine Injection In multiple strengths, the drug maker said in a statement. Read More<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-15903","post","type-post","status-publish","format-standard","hentry","category-latest-news"],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/15903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=15903"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/15903\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=15903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=15903"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=15903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}